As previously reported, Maxim initiated coverage of Lexaria Bioscience with a Buy rating and $2.00 price target. The company is developing DehydraTECH, a formulation technology platform to improve delivery of fat-soluble compounds, with clinical stage programs that include DehydraTECH CBD for hypertension and oral nicotine for the white pouch segment, the analyst tells investors in a research note. Lexaria is also funded to mid-2024 while offering “key value-creating milestones” ahead, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEXX:
- Lexaria Bioscience initiated with a Buy at Maxim
- Lexaria Bioscience granted patent for DehydraTECH-Nicotine
- Lexaria Bioscience announces publication on DehydraTECH-CBD research
- Lexaria Bioscience provides update on DEM-A22-1, EPIL-A21-1 programs
- Lexaria Bioscience reports additional findings from DIAB-A22-1 study